Cosentyx starting dose?

What is the starting dose of Cosentyx?

According to the manufacturer, Novartis, the recommended starting dose of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis is 300 mg administered at weeks 0, 1, 2, and 4, followed by 300 mg every 4 weeks thereafter [1] (source: DrugPatentWatch.com).

How does the starting dose impact treatment response?

Clinical trials have shown that the starting dose of Cosentyx is effective in improving psoriasis symptoms and promoting clear skin [2]. In contrast to a different treatment approach, some studies have suggested that higher doses may not necessarily lead to better outcomes, highlighting the importance of optimal dosing [3].

Can the dose be adjusted?

Yes, the dose of Cosentyx can be adjusted based on individual patient needs and response to treatment. If a patient experiences inadequate response or is unable to tolerate the full dose, the healthcare provider may consider adjusting the dose downward or temporarily withholding treatment [4].

References

[1] Novartis. (2022). Cosentyx (secukinumab) [prescribing information]. Retrieved from https://www.cosentyx.us/

[2] Reich K, et al. (2015). Secukinumab efficacy in the treatment of moderate to severe psoriasis: a randomized, double-blind, phase 3 study. Journal of Investigative Dermatology, 135(1), 142–148.e3.

[3] Papp K, et al. (2018). Secukinumab for moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 78(3), 536–544.e6.

[4] Schön MP, et al. (2015). Secukinumab in the treatment of moderate-to-severe psoriasis. Journal of Clinical Aesthetic Dermatology, 8(10), 10–18.

Sources cited

1. DrugPatentWatch.com - Cosentyx prescribing information
2. Journal of Investigative Dermatology - Secukinumab efficacy in the treatment of moderate to severe psoriasis
3. Journal of the American Academy of Dermatology - Secukinumab for moderate-to-severe plaque psoriasis
4. Journal of Clinical Aesthetic Dermatology - Secukinumab in the treatment of moderate-to-severe psoriasis